 |
Prospector
Profile
1116-01
|
| |
| AlfaCell Corp. |
NAICS |
541710 |
| 300 Atrium Drive
Somerset, NJ 08873 |
Description |
Biotechnology |
| (732) 652-4525 |
Employees |
15 |
| http://www.alfacell.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-8.7550 |
| |
Assets |
(mil) |
7.8200 |
| |
Liability |
(mil) |
3.8720 |
| |
(for the year ended 2007-07-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
AlfaCell Corp. had a net loss of $8,755,144 for the year ended July 31, 2007, much higher than the $7,810,175 and $6,461,920 net losses for the years ended July 31, 2006 and July 31, 2005, respectively. As a result of its recurring losses, the Company's balance sheet showed an accumulated deficit of $92,071,755 as of July 31, 2007.
|
| |
|
Intellectual Property:
The Company has sought to protect technology by applying for, and obtaining, patents and trademark registrations. It has also relied on trade secrets and know-how to protect proprietary technology. The Company continues to develop its portfolio of patents, trade secrets, and know how. It has obtained, and continues to apply for, patents concerning the RNase-based technology. In addition, it has filed foreign counterparts to certain U.S. patent applications. The Company owns a total of 12 registered U.S. patents and 4 patents registered in Europe and Japan as of July 31, 2007. [SEC Filing 10-K 10-15-07]
|
| |
|
Description:
The Company engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions.
|
| |
|
Officers:
Kuslima Shogen (Chair & CEO); Lawrence A. Kenyon (CFO); John P. Brancaccio (Dir.); Stephen K. Carter (Dir.); Donald Conklin (Dir.); James J. Loughlin (Dir.); David Sidransky, M.D. (Dir.); Paul M. Weiss, Ph.D. (Dir.)
|
| |
|
Auditor:
JH Cohn LLP
|
| |
|
Securities:
Common Stock-Symbol ACEL; Nasdaq;
46,555,880 common shares outstanding as of October 10, 2007.
|
| |
| |
| |
| return to main page |
|
|
